Merck to acquire Acceleron and its sotatercept treatment for $11.5Bn
Category: #headlines |   By Hrishikesh Kadam |   Date: 2021-10-02

Merck to acquire Acceleron and its sotatercept treatment for $11.5Bn

Merck, a German science and technology company, has recently announced plans to invest over $11.5 billion to acquire Acceleron Pharma and its potential high blood pressure treatment, sotatercept. The company will reportedly pay $180 per share in cash to buy the Kenilworth, New Jersey-based company.

For the record, the biopharmaceutical company is conducting late-stage clinical studies of sotatercept, a treatment for patients with risks of pulmonary arterial hypertension. According to Mara Goldstein, Mizuho Securities USA analyst, this new treatment represents a potential blockbuster and will serve as a new source of revenue for the technology company. Sources familiar with the matter have seemingly cited that Merck is targeting to launch the drug, with a multi-billion dollar sales potential, in 2024-2025.

The acquisition deal is likely to be closed in the fourth quarter of 2021. Merck is planning to pay for the deal with cash as well as by issuing debt, with no impact on the credit rating. The company’s shares rose 83 cents to $75.92 in the early trading, while the shares of Acceleron slipped 49 cents to $174.87.

Over the past years, Merck has been highly dependent on its drug Keytruda to generate revenue, which is apparently being approved for use in the treatment of various cancer types. The drug brought $4.2 billion for the company in the second quarter of 2021, more than one-third of its total revenue. In addition, it has also been developing a potential COVID-19 treatment, with the trial results from its late-stage research expected to come later in this year.

For those unversed, Acceleron develops and sells Reblozyl, a drug for anemia in rare blood disorders, in partnership with another drug maker, known as Bristol Myers Squibb Co, which is its largest institutional shareholder with an over 11% stake. Various regulators have approved the use of the drug in the U.S., Europe, Australia, and Canada. In the second quarter the biotech company has notably recorded $25.6 million in royalty revenue from the drug, which generated sales of $128 million.

Source credit:

https://www.moneycontrol.com/news/business/merck-spends-11-5-billion-for-acceleron-possible-blockbuster-dr                ug-7528451.html

  • shareShare
  • Twitter
  • Facebook
  • LinkedIn


About Author

Hrishikesh Kadam     Twitter

Hrishikesh Kadam

A graduate in electronics and telecommunication engineering, Hrishikesh Kadam has always found writing fascinating. Driven by a never-ending passion for content creation combined with a bit of experience in writing personal blogs, Hrishikesh blends his technical knowl Read more...

More News By Hrishikesh Kadam

Cloud solution provider Cloopen to acquire Zhuge in cash & stock deal

Cloud solution provider Cloopen to acquire Zhuge in cash & stock deal

By Hrishikesh Kadam

Cloopen Group Holding Limited, one of China’s leading multi-capability cloud-based communications solution providers, has announced that it has made a definitive agreement to purchase complete equity interests in Zhuge Inc., a provider of user-...

Sense raises USD 90 Mn in Series D to expand its HR tech offerings

Sense raises USD 90 Mn in Series D to expand its HR tech offerings

By Hrishikesh Kadam

HR tech firm Sense has multiplied its valuation to USD 500 million in its 50 million Series D fundraise, spearheaded by SoftBank Vision Fund. The five-and-a-half-year-old San Francisco-based startup, which caters to blue-collar workers and assists co...

Mazda Australia faces heat over misleading customers seeking refunds

Mazda Australia faces heat over misleading customers seeking refunds

By Hrishikesh Kadam

The court identified Mazda made 49 distinct fraudulent or misleading representations to nine consumers who sought a refund or replacement of their cars. Australian Competition and Consumer Commission (ACCC) initially filed the case against Mazda, ...